Evotecの空売り状況は、投資家がEvotecの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Evotec (NASDAQ:EVO) 株価情報, 空売り情報

Evotec

Eaton Vance Ohio Municipal Income Trust Shares of Beneficial Interest

Eaton Vance Ohio Municip

Eaton Vance Ohio

Eaton Vance Ohio Municipal Income Trust

AMEX

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Evotec SE

EVO TRANSPORTATION by EVO Transportation & Energy Services, Inc.

EVO Transportation & Energy Services Inc

EVOAIR HOLDINGS INC by EvoAir Holdings Inc.

EvoAir Holdings Inc

EvoAir Holdings Inc Ordinary Shares

Evoke Pharma Inc

SYMBOLIC LOGIC INC by Symbolic Logic Inc.

Symbolic Logic Inc

Evotec SE ((Frankfurt Stock Exchange:EVT, MDAX/TecDAX, TRQX:EVTd, NASDAQ:EVO) announced that, together with Yonsei University and the Korean biotech company Zymedi, it will receive a US$ 4.5m grant from the Korea
Evotec SE ((Frankfurt Stock Exchange:EVT, MDAX/TecDAX, TRQX:<a href="https://www.benzinga.com/stock/EVTd#TRQX">EVTd</a>, NASDAQ:<a href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) announced that, together with Yonsei University and the Korean biotech company Zymedi, it will receive a US$ 4.5m grant from the Korea Institute of Advanced Technology (KIAT). The KIAT grant will fund the development of first-in-class biologic therapies to treat lung diseases, including asthma and idiopathic pulmonary fibrosis (IPF). The project will focus on the preclinical development of novel anti-inflammatory and anti-fibrotic antibodies directed against tRNA synthetases, an emerging therapeutic target class to treat diseases with a high unmet medical need.

Government

News

Evotec Partners with Yonsei University and Zymedi to Develop Lung Disease Therapies with $4.5M Grant

U.S. stock futures were lower this morning, with the Dow futures falling more than 100 points on Friday.
Shares of Ingles Markets, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMKTA#NASDAQ">IMKTA</a>) fell in today's pre-market trading after the company reported results for the three and twelve <a href="https://www.benzinga.com/quote/IMKTA/earnings">months ended Sept. 28</a>.
Net sales fell to $1.40 billion for the recent quarter, down from $1.58 billion in the year-ago period.
Ingles Markets shares fell 1.2% to $65.51 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Viemed Healthcare, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMD#NASDAQ">VMD</a>) shares dipped 6.7% to $7.62 in pre-market trading after gaining 2% on Thursday.</li>
<li>Evotec SE  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) declined 6.6% to $4.56 in pre-market trading following a 2% decline on Thursday.</li>
<li>Nabors Energy Transition Corp. II (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NETD#NASDAQ">NETD</a>) fell 6.3% to $10.11 in pre-market trading.</li>
<li>Third Harmonic Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) fell 4.8% to $10.31 in pre-market trading.</li>
<li>American Public Education, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APEI#NASDAQ">APEI</a>) shares declined 4.7% to $21.26 in pre-market trading.</li>
<li>MINISO Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NYSE">MNSO</a>) fell 3% to $24.37 in pre-market trading.</li>
<li>American Coastal Insurance Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>) dipped 2.6% to $13.30 in pre-market trading.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares slipped 0.7% to $451.12 in pre-market trading after declining around 1.8% on Thursday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42698100/constellium-viracta-therapeutics-and-3-stocks-to-watch-heading-into-friday">Constellium, Viracta Therapeutics And 3 Stocks To Watch Heading Into Friday</a></li>
</ul>

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACIC

APEI

IMKTA

MNSO

NETD

THRD

TSLA

Ingles Markets, Tesla And Other Big Stocks Moving Lower In Friday's Pre-Market Session

<ul>
<li>Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing on cardiometabolic diseases</li>
<li>LAB eN² is also expanding, adding Boston Children's Hospital, Boston University, Johns Hopkins University, Joslin Diabetes Center, and the Icahn School of Medicine at Mount Sinai as new participating institutions</li>
</ul>

Evotec And Novo Nordisk Launch First Projects For LAB eN² Accelerator, Focusing On Cardiometabolic Diseases

Dr Craig Johnstone steps down as Chief OperatingOfficer effective 31 December 2024
Distribution of responsibilities internally
HAMBURG, GERMANY / ACCESSWIRE / November 29, 2024 / Evotec SE ((Frankfurt Stock Exchange: EVT, SDAX/TecDAX, TRQX:<a href="https://www.benzinga.com/stock/EVTd#TRQX">EVTd</a>, NASDAQ:<a href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) today announced that its Chief Operating Officer, Dr Craig Johnstone, will step down and leave the Company effective 31 December 2024. Dr Johnstone joined Evotec in May 2012 as SVP Drug Discovery and Innovation Efficiency and in April 2015 was named President and Site Head, Evotec (France) SAS. Dr. Johnstone was appointed Global Head, Integrated Drug Discovery in January 2017 and became Chief Operating Officer and a member of the Management Board of Evotec on 01 January 2019.

Management

Reported Earlier, Evotec Announces Change In Management Board; Dr Craig Johnstone Steps Down As Chief Operating Officer Effective 31 December 2024; Co Says The Responsibilities Of The COO Function Will Be Distributed Internally Across The Global Operations Leadership Team Until A New Organizational Structure Is Designed And Announced In Line With The Strategic Review

<h3>Gainers</h3>
<ul>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) stock rose 41.7% to $15.39 during Friday's pre-market session. The company's market cap stands at $33.4 million. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) stock rose 34.76% to $0.79. The market value of their outstanding shares is at $6.4 million. </li>
<li>Replimune Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) stock moved upwards by 23.07% to $13.6. The company's market cap stands at $930.4 million. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFW#NASDAQ">LIFW</a>) shares increased by 20.27% to $1.78. The company's market cap stands at $2.2 million. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) stock rose 12.58% to $3.4. The market value of their outstanding shares is at $2.9 million. As per the press release, Q3 earnings came out today. </li>
<li>IO Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) stock rose 12.56% to $0.77. The company's market cap stands at $50.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) stock decreased by 55.0% to $6.08 during Friday's pre-market session. The company's market cap stands at $7.0 million. </li>
<li>Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) stock fell 17.01% to $4.44. The company's market cap stands at $1.5 billion. </li>
<li>Procaps Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROC#NASDAQ">PROC</a>) shares decreased by 14.42% to $0.95. The market value of their outstanding shares is at $107.1 million. </li>
<li>BioXcel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTAI#NASDAQ">BTAI</a>) shares decreased by 8.87% to $0.52. The company's market cap stands at $22.2 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) shares fell 7.93% to $0.29. The company's market cap stands at $4.2 million. </li>
<li>TruBridge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBRG#NASDAQ">TBRG</a>) shares declined by 7.88% to $14.75. The market value of their outstanding shares is at $220.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMIX

BTAI

IOBT

LIFW

PROC

REPL

SCNI

SLXN

TBRG

VRPX

XCUR

12 Health Care Stocks Moving In Friday's Pre-Market Session

Halozyme Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) saw its shares rise on Friday after the company announced it was withdrawing its proposal to acquire Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) for 11 euro ($11.44) per share in cash, implying a fully <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42137175/halozyme-withdraws-proposal-to-acquire-evotec-following-evotecs-unwillingness-to-engage-in-discuss" rel="noreferrer noopener">diluted equity value of 2.0 billion euro.</a>
This move comes after prolonged efforts to engage with Evotec, which expressed its desire to remain independent, Halozyme said.
In addition to this, Halozyme reaffirmed its strong business outlook, with its 2024 guidance signaling continued growth.
The company expects revenue between $970 million and $1.02 billion ($1.003 billion) and an adjusted EBITDA range of $595 million to $625 million, reflecting significant double-digit growth.
Halozyme is confident in its ability to execute its strategy, with the goal of achieving ten approved products with ENHANZE by 2025 and $1 billion in royalty revenue by 2027.
Also Read: <a target="_blank" href="https://www.benzinga.com/economics/macro-economic-events/24/11/42141413/us-business-activity-soars-to-31-month-highs-in-november-small-caps-rally-dow-tops-44000" rel="noreferrer noopener">US Business Activity Soars To 31-Month Highs In November: Small Caps Rally, Dow Tops 44,000</a>
Helen Torley, CEO of Halozyme, explained that although the merger would have created a leading global pharma services company, Evotec was not open to further discussions.
Halozyme&#8217;s efforts to engage with Evotec&#8217;s leadership, including multiple requests for meetings, were unsuccessful, leading to the decision to withdraw the offer.
&#8220;A company spokesperson has publicly commented that its goal is to remain an independent company,&#8221; said Helen Torley,&nbsp;president and chief executive officer of Halozyme regarding Evotec, adding that &#8220;our multiple requests to meet were not accepted&#8221;.
&#8220;Evotec has taken notice of the statement made by Halozyme Therapeutics Inc. on 22 November, stating that it has withdrawn its non-binding proposal to acquire Evotec for EUR11.00 per share in cash,&#8221; Evotec <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/ac42141986/comment-on-withdrawn-non-binding-offer" rel="noreferrer noopener">said in a response.</a>
Price Action: HALO shares are trading higher by 6.21% to $48.54 at last check Friday, while EVO shares are down 18.8% to $4.345.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42137929/2025-us-economy-outlook-cloudier-than-normal-jpmorgan-says-boom-bust-scenarios" target="_blank" rel="noreferrer noopener">2025 US Economy Outlook&#8217; Cloudier Than Normal,&#8217; JPMorgan Says: Boom, Bust Scenarios</a></li>
</ul>

Equities

General

HALO

Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook

WIIM

Evotec shares are trading lower after Halozyme withdrew its €2 billion proposal to acquire the company.

Halozyme Withdraws €2B Proposal To Acquire Evotec After Evotec Declines Engagement, Citing Commitment To Independence; Halozyme Reaffirms 2024 Guidance And Strategic Growth Targets

U.S. stock futures were lower this morning, with the Dow futures falling more than 100 points on Friday's.
Shares of Intuit Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) fell sharply in today's pre-market trading. Intuit reported upbeat results for its first-quarter results, but issued weak forecast <a href="https://www.benzinga.com/news/earnings/24/11/42123997/intuit-shares-fall-after-q1-results-fy25-guidance-below-estimates">for the current quarter</a>.
The company reported quarterly earnings of $2.50 per share, which beat the analyst consensus estimate of $2.35 per share. Quarterly revenue came in at $3.28 billion which beat the consensus estimate of $3.14 billion.
Intuit said it sees second-quarter adjusted earnings of $2.55 to $2.61 per share, versus market estimates of $3.25 per share. The company expects revenue of $3.812 billion to $3.845 billion versus estimates of $3.88 billion.
Intuit shares dipped 5.7% to $639.95 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>AirSculpt Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>) shares dipped 11.5% to $6.00 in pre-market trading.</li>
<li>Carter Bankshares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARE#NASDAQ">CARE</a>) shares fell 10.6% to $16.86 in pre-market trading.</li>
<li>Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) fell 7.3% to $146.50 in pre-market trading. Reddit's shareholder, Advance Magazine Publishers Inc. plans to sell as much as $1.2 billion of the company's stake, reported Bloomberg on Friday morning. The company is said to be offering 7.8 million shares in between the range of $145.38-$148.54 each.</li>
<li>Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) fell 5.2% to $5.07 in pre-market trading</li>
<li>XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) fell 5.1% to $11.66 in pre-market trading.</li>
<li>Central Pacific Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPF#NYSE">CPF</a>) fell 3.6% to $30.25 in pre-market trading.</li>
<li>Materion Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTRN#NYSE">MTRN</a>) fell 2.6% to $110.00 in pre-market trading</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42131399/dow-surges-over-450-points-investor-sentiment-improves-fear-greed-index-moves-to-greed-zone">Dow Surges Over 450 Points As Nvidia Climbs Post-Earnings, Google, Amazon Slip: Fear Index Shifts To &#8216;Greed&#8217; Zone</a></li>
</ul>

AIRS

CARE

INTU

MTRN

RDDT

XPEV

Intuit Issues Weak Forecast, Joins Reddit And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Evotec shares are trading higher after Halozyme Therapeutics confirmed a cobmination offer.

On Thursday, Halozyme Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) submitted a non-binding proposal to Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) to acquire the German company for 11.00 euros per share in cash, implying a fully diluted <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41989694/halozyme-confirms-proposal-to-combine-with-evotec-for-11-00-per-share-in-an-all-cash-transaction" rel="noreferrer noopener">equity value of 2.0 billion euros</a> (around $2.11 billion).
The proposal represents a premium of 109% to Evotec&#8217;s undisturbed share price on&nbsp;October 15, 2024, the day before Triton Partners&#8217; initial accumulation of Evotec shares.
Evotec&nbsp;<a target="_blank" href="https://www.evotec.com/en/about-us/evotec" rel="noreferrer noopener">offers</a> drug discovery and development services to several biotech and pharmaceutical companies.
&#8220;The combination of Halozyme and Evotec would diversify and extend Halozyme revenue and EBITDA growth and durability well into the next decade and beyond,&#8221; said&nbsp;Helen Torley, president and chief executive officer of Halozyme.
Halozyme said its strong cash flow would enable ongoing investments in Evotec&#8217;s early-stage programs and new technologies.
The proposed&nbsp;combination&nbsp;is expected to significantly expand and diversify Halozyme&#8217;s revenue and EBITDA over the next decade. The combined technology offerings would open up new partnership opportunities and program expansions.
Earlier this week, a Bloomberg report highlighted that private equity firm Triton Partners&nbsp;was also considering acquiring Evotec. In an SEC filing, Evotec&nbsp;reported&nbsp;that Triton had acquired a 9.99% stake in the company via several <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41882329/private-equity-triton-partners-takes-around-10-stake-in-evotec-reportedly-mulls-potential-takeover-deal" rel="noreferrer noopener">open-market transactions</a>.
During its second-quarter earnings release, Evotec&nbsp;disclosed it identified a headcount reduction potential of approximately 400 roles (7% of the&nbsp;workforce) across the global footprint and a reduction of the physical footprint by surrendering <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40376143/bristol-myers-german-partner-evotec-plans-layoffs-cites-challenging-revenues-profitability" rel="noreferrer noopener">certain lease agreements</a>.
Evotec&nbsp;exited gene therapy and closed a site in Orth, Austria. It also shut down chemistry activities in Lyon, France, and separated a manufacturing facility in Halle/Westphalia, Germany.
Recently, Halozyme reported third-quarter 2024 revenue of $290.1 million, compared to&nbsp;$216.0 million&nbsp;in the third quarter of 2023.
While announcing its third quarter results, Halozyme raised the fiscal year 2024 adjusted EPS guidance to $4.00-$4.20 from $3.65-$4.05&nbsp;(current consensus $4.15) and revenue guidance to $970 million—$1.02 billion from $935 million—$1.015 billion (current <a href="https://www.benzinga.com/pressreleases/24/10/n41663735/halozyme-reports-third-quarter-2024-financial-and-operating-results" target="_blank" rel="noreferrer noopener">consensus of $1.003 billion</a>).
Evotec <a href="https://www.benzinga.com//node/41994208">responded</a> that it would thoroughly evaluate this expression of interest, determine the appropriate next steps, and communicate its decisions to the capital market in compliance with legal requirements.
Price Action: HALO stock is down 14.8% at $45.97 and EVO stock is up 8.43% at $5.53 at last check Friday.
Image via Pexels
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42013119/whats-going-on-with-large-european-and-us-vaccine-makers" target="_blank" rel="noreferrer noopener">European And US Vaccine Stocks Are Under Pressure &#8211; Here&#8217;s Why</a></li>
</ul>

Biotech

Health Care

Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion

The Company will carefully analyze this expression of interest, decide on next steps, and inform the capital market in accordance with the legal requirements.

Evotec Confirms Receipt Of Non-binding Expression Of Interest From Halozyme Therapeutics With An Offer Price Of EUR 11.00 Per Share

Evotec shares are trading higher after the company announced it received a proposal to be acquired by Halozyme for approximately $2.1 billion.

Halozyme Confirms Proposal To Combine With Evotec For €11/Share All-Cash Transaction

Evotec Shares Resume Trade

Evotec Shares Halted To The Upside; Stock Now 10.33%

Evotec Is Said To Attract Takeover Interest From Halozyme

<h3>Gainers</h3>
<ul>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) stock rose 175.6% to $0.19 during Monday's pre-market session. The market value of their outstanding shares is at $28.9 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares increased by 27.07% to $2.3. The company's market cap stands at $4.2 million. As per the press release, Q3 earnings came out today. </li>
<li>RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) shares increased by 22.7% to $89.0. The market value of their outstanding shares is at $6.5 billion. The company's, Q3 earnings came out today. </li>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) shares increased by 21.95% to $1.0. The company's market cap stands at $3.7 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Vigil Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIGL#NASDAQ">VIGL</a>) shares increased by 21.28% to $4.33. The market value of their outstanding shares is at $171.6 million. As per the press release, Q3 earnings came out 2 days ago. </li>
<li>Evotec (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) shares increased by 19.37% to $4.93. The company's market cap stands at $1.7 billion. As per the news, the Q3 earnings report came out 3 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) shares declined by 48.1% to $1.5 during Monday's pre-market session. The company's market cap stands at $52.3 million. </li>
<li>Fresh2 Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRES#NASDAQ">FRES</a>) shares decreased by 17.3% to $1.1. The company's market cap stands at $26.9 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares declined by 15.55% to $0.34. The market value of their outstanding shares is at $2.1 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) stock fell 13.73% to $3.71. The company's market cap stands at $4.9 million. As per the press release, Q3 earnings came out 2 days ago. </li>
<li>AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) stock decreased by 10.68% to $178.2. The market value of their outstanding shares is at $314.6 billion. </li>
<li>SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) shares fell 8.46% to $2.6. The company's market cap stands at $2.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABBV

CERO

DWTX

FRES

NUWE

RAPT

RDNT

REVB

SNES

TIVC

VIGL

12 Health Care Stocks Moving In Monday's Pre-Market Session

Evotec shares are trading higher following a report suggesting Triton Partners has taken a stake in the company and is considering a potential takeover deal.

Germany-based Evotec SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVO#NASDAQ">EVO</a>) is trading on Monday after a report that suggests the company is a takeover target.
The private equity firm Triton Partners&nbsp;is reportedly considering acquiring Evotec, Bloomberg reported, citing people familiar with the matter.
In an SEC filing, Evotec <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/1412558/000119312524254399/d872020dsc13d.htm" rel="noreferrer noopener">reported</a> that Triton had acquired a 9.99% stake in the company via several open-market transactions.
The company <a target="_blank" href="https://www.evotec.com/en/about-us/evotec" rel="noreferrer noopener">offers</a> drug discovery and development services to several biotech and pharmaceutical companies.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41048867/novo-nordisk-and-evotec-collaborate-on-stem-cell-based-therapy-development" rel="noreferrer noopener">Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development</a>
According to the report, the investment firm has been trying to meet with senior Evotec executives as it looks into a possible buyout.
If Triton wants to increase its stake to 10% or more, it would need approval for foreign investment, the <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-11-11/triton-is-said-to-weigh-takeover-deal-for-drug-developer-evotec" rel="noreferrer noopener">report</a> added.
Any major move would also require backing from Evotec&#8217;s key shareholders, including Novo Holdings, the parent company of Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), and the Abu Dhabi-based Mubadala Investment.
Last week, the German company reported third-quarter revenues of 184.89 million euros, down from 196.28 million a year ago, <a target="_blank" href="https://www.evotec.com/uploads/download-files/IR-ESG-DE/2024-11-06_9M_Analyst-call-presentation.pdf" rel="noreferrer noopener">noting</a> a soft market in shared R&amp;D.
It <a target="_blank" href="https://www.evotec.com/uploads/download-files/IR-ESG/Financial_Publications/Interim-Statement-9M-2024-English.pdf" rel="noreferrer noopener">reported</a> an operating loss of 26.46 million euros, compared to 12.19 million euros loss a year ago.
In its second-quarter earnings, Evotec&#8217;s CEO said the company is operating in a more challenging market environment, notably the slowdown of <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40376143/bristol-myers-german-partner-evotec-plans-layoffs-cites-challenging-revenues-profitability" rel="noreferrer noopener">early-stage R&amp;D spending</a>.
In October, Evotec announced advancements in its strategic partnership with&nbsp;Bristol-Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), which is&nbsp;focused on developing a molecular <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41490865/why-is-evotec-stock-gaining-today" rel="noreferrer noopener">glue-based pipeline</a>.
Price Action: EVO stock is up 16.2% at $4.80 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/41877517/ge-healthcare-and-deephealth-team-up-to-advance-ai-powered-breast-cancer-screening" target="_blank" rel="noreferrer noopener">GE HealthCare And DeepHealth Team Up To Advance AI-Powered Breast Cancer Screening: Details</a></li>
</ul>

Rumors

Media

Private Equity Triton Partners Takes Around 10% Stake In Evotec, Reportedly Mulls Potential Takeover Deal

Halozyme gains after withdrawing Evotec bid

Evotec (EVO) issued the following comment on the withdrawn non-binding offer: "Evotec SE has taken notice of the statement made by Halozyme (HALO) ...

Evotec takes notice of Halozyme withdrawal, convicted in standalone strategy

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Amazon (AMZN) will invest an additiona...

Amazon invests $4B more in Anthropic, Gap reports Q3 beat: Morning Buzz

RBC Capital analyst Charles Weston maintained a Buy rating on Evotec (0IRF – Research Report) today and set a price target of €11.60. The company's...

RBC Capital Sticks to Their Buy Rating for Evotec (0IRF)

Deutsche Bank analyst Falko Friedrichs maintained a Sell rating on Evotec (0IRF – Research Report) today and set a price target of €4.00. The compa...

Evotec (0IRF) Gets a Sell from Deutsche Bank

Halozyme: Growth Amid Uncertainty After Failed Acquisition (Rating Downgrade)

Evotec (EVO) announced that its Chief Operating Officer, Dr Craig Johnstone, will step down and leave the company effective December 31. Dr Johnsto...

Evotec Chief Operating Officer to step down on December 31

In a report released today, Christian Ehmann from Warburg Research maintained a Buy rating on Evotec (0IRF – Research Report), with a price target ...

Warburg Research Keeps Their Buy Rating on Evotec (0IRF)

Evotec: Some Recovery Has Come, But Much More Is Expected

Halozyme: Recent Approvals Alter My Appetite

ALGT

AMZN

BIDU

DXLG

ESTC

EVOTF

GRAB

IESC

MATW

SQNXF

TMDX

VWAGY

VWAPY

Press Releases

Evotec Announces Sale of API Manufacturing Facility to Monacum Partners

Earnings

Evotec SE Reports 9M 2024 Results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions

Halozyme Confirms Proposal to Combine with Evotec for €11.00 Per Share in an All-Cash Transaction

Comment on Media Report

Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec

Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions

Comment on Withdrawn Non-Binding Offer

Evotec Announces Change in Management Board

Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk

Evotec Receives Grant from Korean Government to Develop Novel Antibody-based Treatments for Lung Diseases

Comments

Evotec

空売り

Evotec (NASDAQ:EVO) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル